Armata Pharmaceuticals, Inc. (ARMP) Reports Q2 Loss, Beats Revenue Estimates

Group 1 - Armata Pharmaceuticals reported a quarterly loss of $0.32 per share, better than the Zacks Consensus Estimate of a loss of $0.39, and improved from a loss of $0.65 per share a year ago, resulting in an earnings surprise of +17.95% [1] - The company achieved revenues of $2.17 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 57.17%, compared to zero revenues a year ago [2] - Armata Pharmaceuticals shares have increased approximately 27.6% since the beginning of the year, outperforming the S&P 500's gain of 8.4% [3] Group 2 - The earnings outlook for Armata Pharmaceuticals is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The estimate revisions trend for Armata Pharmaceuticals was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.50 on $1.38 million in revenues, and -$1.94 on $5.5 million in revenues for the current fiscal year [7] Group 3 - The outlook for the Medical - Biomedical and Genetics industry, to which Armata Pharmaceuticals belongs, is currently in the bottom 43% of over 250 Zacks industries, which may impact stock performance [8] - Another company in the same industry, Invivyd, Inc., is expected to report a quarterly loss of $0.04 per share, reflecting a year-over-year change of +90%, with revenues projected at $15.5 million, up 585.8% from the previous year [9]